Effect of nifedipine and theophylline in asthma.
The effect of nifedipine, 10 mg po q.i.d. for 2 weeks, was studied in a randomized, double-blind, crossover trial in nine patients with asthma receiving theophylline. Nifedipine did not significantly affect the mean (+/- SD) morning peak expiratory flow rate (PEFR; 336 +/- 130 L/min for drug vs. 349 +/- 92 L/min for placebo), evening PEFR (393 +/- 69 L/min for drug vs. 367 +/- 66 L/min for placebo), symptom score (27.4% +/- 22.9% for drug vs. 33.8% +/- 26.4% for placebo), or the number of albuterol inhalations per day (5.8 +/- 3.5 for drug vs. 6.2 +/- 4.1 for placebo). Furthermore, there was no change in PEFR 30, 60, or 120 minutes after nifedipine dosing. Nifedipine did not significantly affect the steady-state serum theophylline trough levels (9.1 +/- 2.2 mg/ml for drug vs. 10.2 +/- 1.9 micrograms/ml for placebo) or the theophylline pharmacokinetic parameters, such as the elimination t1/2, peak serum concentration, time to peak, and AUC(0-24). We conclude that nifedipine has little, if any, effect on the clinical status, PEFR, or theophylline serum levels in patients with asthma who receive theophylline.
D000328:Adult; D000368:Aged; D000818:Animals; D001249:Asthma / Q000188:drug therapy* / Q000378:metabolism; D004311:Double-Blind Method; D004341:Drug Evaluation; D004347:Drug Interactions; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000494:pharmacology*; D010366:Peak Expiratory Flow Rate; D011897:Random Allocation; D013806:Theophylline / Q000378:metabolism / Q000627:therapeutic use*
D013806:Theophylline; D009543:Nifedipine